About Bristol Myers Squibb
We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. At Bristol Myers Squibb, we are in the business of breakthroughs—the kind that transform patients’ lives through lifesaving, innovative medicines. Our business combines the agility of a biotech with the reach and resources of an established pharmaceutical company to create a leading global biopharma company. With a diverse and promising pipeline, we focus on innovations that drive meaningful change in:
We bring a human touch to every treatment we pioneer. Our symbol, the hand, is a simple, universal expression of healing, of giving and receiving care. It is a representation of humanity; of the personal touch we bring to our work. Our brand fully embodies our vision and embraces our commitment to compassionate science and putting patients and people first.
Acquisitions of Celgene and MyoKardia
After completing our acquisition of Celgene in late 2019, Bristol Myers Squibb acquired MyoKardia in October 2020, creating a leading biopharma company with a diversified portfolio of leading medicines targeting oncology, hematology, immunology and cardiovascular diseases. Even after these two acquisitions, we maintain our focus on creating even more value for patients through our financial flexibility and continued innovation.
Our Commitment
To our patients and customers, workforce, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of every product is the integrity of its maker. We operate with effective governance and high standards of ethical behavior. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs. We take our commitment to economic, social and environmental sustainability seriously, and extend this expectation to our partners and suppliers. As a responsible corporate citizen, we seek to actively improve the health of the communities where we live, work and serve. Around the globe, we promote health equity and seek to promote the health outcomes of populations disproportionately affected by serious disease. We believe our inclusive culture supports better outcomes for all patients, and we seek diversity in all aspects of our business.
To our patients and customers
We commit to scientific excellence and investment in biopharmaceutical research and development to provide innovative, high-quality medicines that address the unmet medical needs of patients with serious diseases. We apply scientific rigor to produce clinical and economic benefit through medicines that improve patients’ lives. We make information about our commercialized medicines widely and readily available. We actively seek to improve access to care, advocate for policies that promote health equity, and help underserved patients access and afford the medicines they need.
To our workforce
We embrace a diverse workforce and inclusive culture. The health, safety, professional development, work-life balance and equitable, respectful treatment of our employees is one of our highest priorities. We commit to ensuring our colleagues have opportunities for development and advancement. We commit to hiring and developing a workforce that reflects the changing diversity of our communities and our patients.
To our shareholders
We strive to produce sustained strong performance and shareholder value.
To our suppliers
We believe in the positive economic impact of engaging diverse suppliers. We are committed to working with suppliers that represent the diversity of our employees and the communities where we live and work.
To our environment
We encourage the preservation of natural resources and strive to minimize the environmental impact of our operations and products.
